GlassScriptPhysician profile
Henry Dewitt Rodeffer
NPI 1710978077
$9,803.41
in general payments reported to CMS, 2019-2025
55 companies · $1,209 in 2025
The $1,209 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $561 · 2021: $2,457 · 2022: $1,760 · 2023: $1,761 · 2024: $1,233 · 2025: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,202.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,437.50 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $746.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $731.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $697.11 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $582.28 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $563.46 | 2019-2023 | Repatha, Otezla |
| Novo Nordisk INC | $550.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $398.95 | 2019-2024 | Jardiance, Synjardy |
| Abbott Laboratories | $395.87 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $308.57 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.32 | 2019-2023 | Xifaxan, Trulance |
| Astellas Pharma US INC | $299.54 | 2020-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $270.72 | 2019-2022 | |
| Boston Scientific Corporation | $250.20 | 2019-2024 | Bionic Navigator |
| Sanofi-Aventis U.S. LLC | $212.69 | 2019-2023 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Rodeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.